Results 141 to 150 of about 3,139,231 (313)
Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy for locally advanced rectal cancer: 3-year survival from a phase 2 study. [PDF]
BMC MedLin Z +17 more
europepmc +1 more source
High-grade serous ovarian cancer 3 years after bilateral salpingectomy: A case report. [PDF]
Mol Clin Oncol, 2017 Sato E +5 more
europepmc +1 more source
Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
Molecular Oncology, EarlyView.WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute +17 more
wiley +1 more source
Development of an <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography-based visceral pleural invasion prediction index in peripheral subpleural non-small cell lung cancer ≤3 cm. [PDF]
Quant Imaging Med SurgZhang H +7 more
europepmc +1 more source
Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells
Molecular Oncology, EarlyView.We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller +17 more
wiley +1 more source